Cannabis Law Report

OCTOBER 22, 2021

The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana – Cannabidiol pipeline landscape.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). What are the common adverse events noted in clinical trials examining the efficacy of cannabinoids for ASD? 17 Aug 2021. Fletcher S. Fletcher S.

Clinical Trials 52

Clinical Trials Events Therapy Sleep 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

TheAnswerPage

MAY 29, 2021

A common adverse effect of chronic recreational marijuana use is cannabinoid hyperemesis syndrome. In fact, cannabinoid hyperemesis syndrome is a near daily diagnosis in many Canadian emergency departments. Anecdotal evidence supports the use of haloperidol to treat cannabinoid hyperemesis syndrome. mg/kg or 0.1 Ruberto, A.,

Clinical Trials 52

Clinical Trials Cannabinoids Treatment Recreational 52

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021. On 5 August 2021, the TGA announced that an Independent Expert Panel had been established to undertake the review. The review excludes pre-clinical trials (i.e.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JANUARY 27, 2022

The majority of industry-sponsored drugs in active clinical development for FXS are in Phase II, with two drugs in Phase III. The distribution of clinical trials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

Clinical Trials 52

Clinical Trials Therapy Cannabinoids Topical 52

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Veriheal

MAY 2, 2022

Israeli biotechnology company Cannabotech may have hit the nail on the head, with the company recently confirming that their unique medicinal cannabis-based treatment successfully killed 90% of cancer cells in laboratory tests. The Future of Cannabinoids and Cancer. The Future of Cannabinoids and Cancer.

Treatment 97

Treatment Clinical Trials Patients Medicine 97

Puff Puff Post

DECEMBER 28, 2018

The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. Instead, CBD is being used.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

AUGUST 13, 2021

Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

The Cannigma

JANUARY 13, 2023

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” 7 A 2021 study of a medical cannabis cohort reported that high THC / low CBD flower was the most preferred cannabis type in migraine patients.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

OCTOBER 18, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Marijuana – Cannabidiol – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. Cannabis oil: TO Pharmaceuticals.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

JUNE 30, 2021

LONDON–(BUSINESS WIRE)– Fourfive , the CBD and nutrition brand loved by athletes and those leading an active lifestyle, today called on the UK’s sports governing bodies to stop sitting if on the fence and conduct clinical trials into the effectiveness of CBD and medicinal cannabis in professional sport.

Medicine 75

Medicine Clinical Trials CBD Sleep 75

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The May 4, 2021 guidance for revenue was in the range of $2.5 – $2.7 That has been increased as of June 17, 2021, to a range of $3.0

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Cannabis Law Report

NOVEMBER 1, 2021

The findings have been published in an abstract in the October 2021 supplement of HEPATOLOGY , a premier peer-reviewed publication in the field of liver disease published on behalf of the AASLD. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? It was also unique because it used whole-plant cannabis, rather than single-molecule extracts or synthetic pharmaceutical cannabinoids. .

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

The Cannigma

MAY 13, 2022

Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. There have been a number of preclinical and clinical trials studying cannabis’ effects on pain. When this system alone can’t manage the pain, outside cannabinoids like THC can help.

Terpenes 111

Terpenes Strains Chronic Pain Clinical Trials 111

The Cannigma

JUNE 23, 2022

While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. What is the difference between CBG and CBGa? What does CBGA do?

Cannabinoids 113

Cannabinoids Research and Development Clinical Trials Extraction 113

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 5] The Journal of the American Medical Association published similar findings in May 2021. [6].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Not only did the success influence the European Commission to approve Epidoliolex , but it also sparked motivation to develop a similar treatment for other disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

FEBRUARY 3, 2022

million in 2021, and is projected to reach USD 176,005.5 million by 2030 at a CAGR of 23.9%, 2021-2030. The combined effects of both cannabinoids (THC and CBD) have their health advantages, but when taken at once. Growing Adoption of Medical Cannabis for the Treatment of Chronic Compounds. 2564 (2021). Restraints.

Indica 52

Indica Oil Legalization Research and Development 52

Healer

DECEMBER 17, 2021

November 5, 2021. Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Most of the clinically relevant interactions of CBD with other drugs are related to competition in the liver’s detoxification pathways. References.

CBD 98

CBD THC Conditions Medicine 98

Healer

MARCH 26, 2021

March 19, 2021. Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. Some researchers believe cannabis can help wean prescription opioid users off the addictive and potentially deadly drugs.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111